{"id":23161,"date":"2023-01-04T15:29:00","date_gmt":"2023-01-04T07:29:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23161"},"modified":"2025-01-26T15:34:03","modified_gmt":"2025-01-26T07:34:03","slug":"inscinstech-raises-rmb-150-million-in-series-a-b-and-b-rounds","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23161","title":{"rendered":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds"},"content":{"rendered":"\n

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.<\/p>\n\n\n\n

Funding and Future Plans<\/strong>
The proceeds from these financing rounds will be directed towards the research and development (R&D) of upstream Chemistry, Manufacturing, and Controls (CMC) process and tool products. Inscinstech plans to use the funds to enhance its manufacturing capacity and expand its global market presence. This strategic allocation of resources underscores the company’s commitment to innovation and growth in the biotechnology sector.<\/p>\n\n\n\n

Company Background and Product Portfolio<\/strong>
Inscinstech operates R&D centers in Suzhou and Beijing, China, as well as in Boston, Massachusetts, in the United States. The company is known for its advanced product portfolio, which includes a protein purification system, large – scale nucleic acid synthesis instrument, nano drug assembly system, and other innovative biotech tools. These products are designed to improve the efficiency and effectiveness of biological separation processes, positioning Inscinstech as a key player in the global biotechnology market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,3209],"class_list":["post-23161","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-inscinstech"],"yoast_head":"\nInscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23161\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23161\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T07:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T07:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds\",\"datePublished\":\"2023-01-04T07:29:00+00:00\",\"dateModified\":\"2025-01-26T07:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161\"},\"wordCount\":232,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Inscinstech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23161#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23161\",\"name\":\"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-04T07:29:00+00:00\",\"dateModified\":\"2025-01-26T07:34:03+00:00\",\"description\":\"Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23161\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23161#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds - Insight, China's Pharmaceutical Industry","description":"Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23161","og_locale":"en_US","og_type":"article","og_title":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23161","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-04T07:29:00+00:00","article_modified_time":"2025-01-26T07:34:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23161#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23161"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds","datePublished":"2023-01-04T07:29:00+00:00","dateModified":"2025-01-26T07:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23161"},"wordCount":232,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Inscinstech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23161#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23161","url":"https:\/\/flcube.com\/?p=23161","name":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-04T07:29:00+00:00","dateModified":"2025-01-26T07:34:03+00:00","description":"Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully raised a total of RMB 150 million (USD 21.73 million) across its Series A+, B, and B+ financing rounds. The funding rounds were led by ESCO Lifesciences Group, Luxin Venture Capital, and Qiming Venture Partners, respectively, with additional contributions from Qianhai Infrastructure Investment Fund, Jintou Zhiyuan (Jiangsu) Equity Investment Fund, Addor Capital, and Matrix Partners.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23161#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23161"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23161#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23161"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23161\/revisions"}],"predecessor-version":[{"id":23162,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23161\/revisions\/23162"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}